AstraZeneca’s Imfinzi Scores Hit In Bladder Cancer But Misses In NSCLC

The success in the NIAGRA bladder cancer study is welcome, but another failure in NSCLC means AstraZeneca has more riding on the AEGEAN study, with an FDA advisory board to review the lung cancer data due shortly.